Levofloxacin: update and perspectives on one of the original ‘respiratory quinolones’

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Expert Review of Anti-Infective Therapy

• Publication date

  2003-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14787210.1.3.371PMID 15482135
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of quinolone resistance

  2005cited by this paper
• Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections.

  2003cited by this paper
• Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.

  2003cited by this paper
• Effects of three fluoroquinolones on QT interval in healthy adults after single doses

  2003cited by this paper
• High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.

  2003cited by this paper
• MECHANISMS OF QUINOLONE RESISTANCE

  2003cited by this paper
• Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in Indonesia.

  2003cited by this paper
• Dual activity of fluoroquinolones against Streptococcus pneumoniae.

  2003cited by this paper
• Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

  2003cited by this paper
• Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

  2003cited by this paper
• Antimicrobial-Drug Prescription in Ambulatory Care Settings, United States, 1992–2000

  2003cited by this paper
• Fluoroquinolone-associated tendinopathy: a critical review of the literature.

  2003cited by this paper
• Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

  2003cited by this paper
• Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy.

  2003cited by this paper
• Levofloxacin: an updated review of its use in the treatment of bacterial infections.

  2003cited by this paper
• Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs.

  2002cited by this paper
• Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.

  2002cited by this paper
• Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae.

  2002cited by this paper
• A critical review of the fluoroquinolones: focus on respiratory infections.

  2002cited by this paper
• Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

  2002cited by this paper
• Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

  2002cited by this paper
• The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?

  2002cited by this paper
• Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.

  2002cited by this paper
• A Critical Review of the Fluoroquinolones

  2002cited by this paper
• Widespread use of fluoroquinolones versus emerging resistance in pneumococci.

  2002cited by this paper
• Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

  2002cited by this paper
• Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae.

  2002cited by this paper
• Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial.

  2002cited by this paper
• Pharmacokinetics of Intravenous and Oral Levofloxacin in Critically Ill Adults in a Medical Intensive Care Unit

  2002cited by this paper
• Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates.

  2001cited by this paper
• Evaluation of Current Activities of Fluoroquinolones against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance

  2001cited by this paper
• Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.

  2001cited by this paper
• Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.

  2001cited by this paper
• Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin

  2001cited by this paper
• Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae

  2001cited by this paper
• Pharmacodynamics of Fluoroquinolones againstStreptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections

  2001cited by this paper
• In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae.

  2001cited by this paper
• Gatifloxacin, an Advanced 8‐Methoxy Fluoroquinolone

  2001cited by this paper
• HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae.

  2001cited by this paper
• Risk Assessment for Antimicrobial Agent‐Induced QTc Interval Prolongation and Torsades de Pointes

  2001cited by this paper
• Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

  2001cited by this paper
• Fluoroquinolone Adverse Effects and Drug Interactions

  2001cited by this paper
• Nontyphoidal salmonellosis.

  2001cited by this paper
• Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

  2001cited by this paper
• Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.

  2000cited by this paper
• Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

  2000cited by this paper
• The safety profile of the fluoroquinolones.

  2000cited by this paper
• Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.

  2000cited by this paper
• Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults

  2000cited by this paper
• Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.

  2000cited by this paper
• Fluoroquinolone Action against Clinical Isolates ofMycobacterium tuberculosis: Effects of a C-8 Methoxyl Group on Survival in Liquid Media and in Human Macrophages

  1999cited by this paper
• Fluoroquinolone toxicity profiles: a review focusing on newer agents.

  1999cited by this paper
• ParC and GyrA May Be Interchangeable Initial Targets of Some Fluoroquinolones in Streptococcus pneumoniae

  1999cited by this paper
• QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.

  1999cited by this paper
• Primary Targets of Fluoroquinolones inStreptococcus pneumoniae

  1999cited by this paper
• Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.

  1999cited by this paper
• Pharmacokinetics and Safety of High-Dose and Extended-Interval Regimens of Levofloxacin in Human Immunodeficiency Virus-Infected Patients

  1999cited by this paper
• Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong

  1999cited by this paper
• A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

  1999cited by this paper
• QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.

  1999cited by this paper
• Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

  1999cited by this paper
• The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.

  1999cited by this paper
• Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.

  1999cited by this paper
• Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

  1999cited by this paper
• Pharmacodynamic Comparisons of Levofloxacin, Ciprofloxacin, and Ampicillin against Streptococcus pneumoniae in an In Vitro Model of Infection

  1999cited by this paper
• Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.

  1998cited by this paper
• Penetration of Levofloxacin into Lung Tissue after Oral Administration to Subjects Undergoing Lung Biopsy or Lobectomy

  1998cited by this paper
• Double-Blind Evaluation of the Safety and Pharmacokinetics of Multiple Oral Once-Daily 750-Milligram and 1-Gram Doses of Levofloxacin in Healthy Volunteers

  1998cited by this paper
• Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy

  1998cited by this paper
• Levofloxacin, a Second‐Generation Fluoroquinolone

  1998cited by this paper
• Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.

  1998cited by this paper
• Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report.

  1997cited by this paper
• DNA gyrase, topoisomerase IV, and the 4-quinolones

  1997cited by this paper
• The Clinical Pharmacokinetics of Levofloxacin

  1997cited by this paper
• Quinolone arthropathy in animals versus children.

  1997cited by this paper
• Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.

  1997cited by this paper
• Transport of levofloxacin in a kidney epithelial cell line, LLC-PK1: interaction with organic cation transporters in apical and basolateral membranes.

  1996cited by this paper
• Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

  1996cited by this paper
• Transport of levofloxacin in a kidney epithelial cell line, LLC-PK[1] : interaction with organic cation transporters in apical and basolateral membranes

  1996cited by this paper
• Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

  1996cited by this paper
• Dissociated resistance among fluoroquinolones

  1994cited by this paper
• Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

  1993cited by this paper
• Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

  1993cited by this paper
• Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

  1989cited by this paper

• Marmosets as models of infectious diseases

  2024cites this paper
• Population pharmacokinetics of antibacterial agents in the older population: a literature review

  2023cites this paper
• Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis

  2022cites this paper
• A review study of Antibiotics with Antiviral and Anti-inflammatory Potential against Covid-19.

  2022cites this paper
• Treatment of chronic bacterial prostatitis

  2018cites this paper
• Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?

  2018cites this paper
• Acute Bacterial prostatitis II Chronic Bacterial Prostatitis III Chronic Prostatitis / Chronic Pelvic Pain Syndrome a ) Inflammatory b ) Non-Inflammatory IV Asymptomatic Inflammatory Prostatitis

  2018cites this paper
• A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?

  2014cites this paper
• Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes.

  2012cites this paper
• Bioavailability and Efficacy of Levofloxacin against Francisella tularensis in the Common Marmoset (Callithrix jacchus)

  2010cites this paper
• Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment.

  2010cites this paper
• Francisella tularensis : The bioavailability and efficacy of levofloxacin in the 1 common marmoset

  2010cites this paper
• Permeability and Concentration of Levofloxacin in Epithelial Lining Fluid in Patients With Lower Respiratory Tract Infections

  2010cites this paper
• Bioavailability and Efficacy of Levofloxacin against Francisella tularensis in the Common Marmoset ( Callithrix jacchus ) (cid:1)

  2010cites this paper
• Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration.

  2008cites this paper
• Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia.

  2007influential citation
• Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.

  2006cites this paper
• Pharmacokinetic Considerations and Efficacy of Levofloxacin in an Inhalational Anthrax (Postexposure) Rhesus Monkey Model

  2006cites this paper
• Quinolones in 2005: an update.

  2005cites this paper
• Efflux-mediated antimicrobial resistance.

  2005cites this paper
• Therapie bakterieller Infektionen in der pädiatrischen Onkologie

  2005cites this paper
• [Bacterial infections in pediatric cancer patients].

  2005cites this paper
• Common Marmoset(Callithrix jacchus)에서의 복부 초음파에 관한 연구

  2001cites this paper